Table 2 Diagnosis, management, and concomitant disease or complication of VL from 2015 to 2016 at UoG-LRTC and MSF-KTC northwest Ethiopia, 2017
Variables | Treatment facilities | |
|---|---|---|
MSF-KTC (n = 303) | UoG-LRTC (n = 299) | |
n (%) | n (%) | |
Diagnosis | ||
Serological and/or clinical | 283 (93.4) | 30 (10) |
Parasitological | 20 (6.6) | 269 (90) |
Site of aspiration | ||
Spleen | 17 (5.6) | 220 (73.6) |
Bone marrow | 3 (1) | 49 (16.4) |
Anti leishmaniasis treatment | ||
SSG-PM | 215 (71) | 269 (90) |
Ambisome | 88 (29) | 30 (10) |
Treatment outcome | ||
Cured | 294 (97) | 295 (98.7) |
Failure | 9 (3) | 4 (1.3) |
Nutrition support | ||
Yes | 205 (67.7) | 3 (1) |
No | 98 (32.3) | 296 (99) |
Concomitant diseases/complications | ||
Malaria | 15 (5) | 31 (10.4) |
Pneumonia | 83 (27.4) | 42 (14) |
Ear infection | 13 (4.3) | 12 (4) |
Intestinal parasite | 58 (19.1) | 64 (21.4) |
Skin fungal infection | 3 (1) | 19 (6.4) |
Pancreatitis | 2 (0.7) | 10 (3.3) |
Sever Neutropenia (< 500 neutrophils count) | 65 (21.5) | 43 (14.4) |
Othersa | 25 (8.3) | 12 (4) |